p57KIP2 targeted disruption and Beckwith-Wiedemann syndrome: is the inhibitor just a contributor?

Bioessays. 1997 Oct;19(10):839-42. doi: 10.1002/bies.950191002.

Abstract

Beckwith-Wiedemann syndrome is a human congenital disorder characterized by a wide variety of growth abnormalities, including developmental defects and predisposition to certain tumors. Genetic evidence has suggested a role for p57KIP2, a member of a family of cell cycle inhibitory genes, in Beckwith-Wiedemann syndrome. Two independent groups have reported the generation and characterization of mice lacking functional p57KIP2. These mice demonstrate a number of abnormal phenotypes which overlap with, although do not completely recapitulate, Beckwith-Wiedemann syndrome. These findings advance the molecular characterization of a human disorder, and provide insight into the interplay between regulation of cell division and development.

Publication types

  • Review

MeSH terms

  • Abnormalities, Multiple / genetics
  • Animals
  • Beckwith-Wiedemann Syndrome / genetics*
  • Cell Cycle / genetics
  • Cyclin-Dependent Kinase Inhibitor p57
  • Enzyme Inhibitors
  • Humans
  • Insulin-Like Growth Factor II / biosynthesis
  • Insulin-Like Growth Factor II / genetics
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Nuclear Proteins / deficiency*
  • Nuclear Proteins / genetics*

Substances

  • CDKN1C protein, human
  • Cdkn1c protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p57
  • Enzyme Inhibitors
  • Nuclear Proteins
  • Insulin-Like Growth Factor II